Vnitr Lek 2018, 64(2):136-145 | DOI: 10.36290/vnl.2018.021

Life threatening manifestations of lupus and antiphospholipid syndrome in internal medicine

Pavel Horák*, Martina Skácelová, Jiří Vymětal, Markéta Schubertová
III. interní klinika - nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc

The clinical picture of systemic lupus and antiphospholipid syndrome is remarkably varied and disease manifestations are commonly very heterogeneous. Relatively often both diseases are associated with severe, acute and life threatening manifestations, which places demands on the knowledge of differential diagnostics and experience of the physicians. This article deals with the serious and mostly acute impairment of cardiovascular, respiratory, renal, gastrointestinal, hematopoietic or nervous systems, briefly discusses the acute pregnancy complication and summarizes the basic therapeutic option. It emphasizes the role of both, sometimes inseparable, diseases in differential diagnosis of acute symptoms in internal medicine.

Keywords: clinical symptoms; diagnostics; live threatening manifestations; lupus erythematosus; systemic antiphospholipid syndrome; therapy

Received: September 26, 2017; Accepted: November 19, 2017; Published: February 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák P, Skácelová M, Vymětal J, Schubertová M. Life threatening manifestations of lupus and antiphospholipid syndrome in internal medicine. Vnitr Lek. 2018;64(2):136-145. doi: 10.36290/vnl.2018.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Petri M, Orbai AM, Alarcon GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64(8): 2677-2686. Dostupné z DOI: <http://dx.doi.org/10.1002/art.34473. Go to original source... Go to PubMed...
    2. Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun 2014; 48-49: 20-25. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaut.2014.01.006>. Go to original source... Go to PubMed...
    3. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4(2): 295-306. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1538-7836.2006.01753.x>. Go to original source... Go to PubMed...
    4. Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: a clinical review. J Nephropathol 2014; 3(1): 9-17. Dostupné z DOI: <http://dx.doi.org/10.12860/jnp.2014.03>. Go to PubMed...
    5. Galve E, Candell-Riera J, Pigrau C et al. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 1988; 319(13): 817-823. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM198809293191302>. Go to original source... Go to PubMed...
    6. Doria A, Iaccarino L, Sarzi-Puttini P et al. Cardiac involvement in systemic lupus erythematosus. Lupus 2005; 14(9): 683-686. Dostupné z DOI: <http://dx.doi.org/10.1191/0961203305lu2200oa>. Go to original source... Go to PubMed...
    7. Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 1999; 74(3): 275-284. Dostupné z DOI: <http://dx.doi.org/10.4065/74.3.275>. Go to original source... Go to PubMed...
    8. Akdogan A, Kilic L, Dogan I et al. Pulmonary hypertension in systemic lupus erythematosus: pulmonary thromboembolism is the leading cause. J Clin Rheumatol 2013; 19(8): 421-425. Dostupné z DOI: <http://dx.doi.org/10.1097/RHU.0000000000000037>. Go to original source... Go to PubMed...
    9. Bazzan M, Vaccarino A, Marletto F. Systemic lupus erythematosus and thrombosis. Thrombosis J 2015; 13: 16. Dostupné z DOI: <http://dx.doi.org/10.1186/s12959-015-0043-3>. Go to original source... Go to PubMed...
    10. Smržová A, Horák P, Skácelova M et al. Cardiovascular events in patients with systemic lupus erytematodes. Cor vasa 2014; 56(2): e145-e152. Go to original source...
    11. Mira-Avendano IC, Abril A. Pulmonary manifestations of Sjögren syndrome, systemic lupus erythematosus, and mixed connective tissue disease. Rheum Dis Clin North Am 2015; 41(2): 263-277. Dostupné z DOI: <http://dx.doi.org/10.1016/j.rdc.2015.01.001>. Go to original source... Go to PubMed...
    12. Martinez-Martinez MU, Abud-Mendoza C. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus. Clinical manifestations, treatment, and prognosis. Reumatol Clin 2014; 10(4): 248-253. Dostupné z DOI: <http://dx.doi.org/10.1016/j.reuma.2014.02.002>. Go to original source... Go to PubMed...
    13. Martinez-Taboada VM, Blanco R, Armona J et al. Acute reversible hypoxemia in systemic lupus erythematosus: a new syndrome or an index of disease activity? Lupus 1995; 4(4): 259-262. Dostupné z DOI: <http://dx.doi.org/10.1177/096120339500400405>. Go to original source... Go to PubMed...
    14. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15(2): 241-250. Erratum in J Am Soc Nephrol. 2004; 15(3): 835-836. Go to original source... Go to PubMed...
    15. Hughson MD, Nadasdy T, McCarty GA et al. Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Kidney Dis 1992; 20(2): 150-158. Go to original source... Go to PubMed...
    16. Dhingra S, Qureshi R, Abdellatif A et al. Tubulointerstitial nephritis in systemic lupus erythematosus: innocent bystander or ominous presage. Histol Histopathol 2014; 29(5): 553-565. Dostupné z DOI: <http://dx.doi.org/10.14670/HH-29.10.553>. Go to PubMed...
    17. Tian XP, Zhang X. Gastrointestinal involvement in systemic lupus erythematosus: Insight into pathogenesis, diagnosis and treatment. World J Gastroenterol 2010; 16(24): 2971-2977. Go to original source... Go to PubMed...
    18. Rahme E, Barkun A, Nedie H et al. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008; 103(4): 872-882. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1572-0241.2008.01811.x>. Go to original source... Go to PubMed...
    19. Rouf A, Uddin R, Hoque E. Pattern of hematological manifestations in patients with systemic lupus erythematosus attending in a tertiary care hospital. Medical College Journal 2014; 13(1): 49-53. Dostupné z DOI: <http://dx.doi.org/10.3329/cmoshmcj.v13i1.19420>. Go to original source...
    20. Aleem A, Al Arfaj AS, Khalil N et al. Haematological abnormalities in systemic lupus erythematosus. Acta Reumatol Port 2014; 39(3): 236-241. Go to PubMed...
    21. Giannouli S, Voulgarelis M, Ziakas PD et al. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis; 2006: 65(2): 144-144. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2005.041673>. Go to original source... Go to PubMed...
    22. Lansigan F, Isufi I, Tagoe CE. Microangiopatic haemolytic anemia resembling trombocytopenic purpura in SLE: the role of ADAMTS 13. Rheumatology (Oxford) 2011; 50(5): 824-829. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/keq395>. Go to original source... Go to PubMed...
    23. Vilaiyuk S, Sirachainan N, Wanitkun S et al. Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review. Clinical Rheumatology 2013; 32(6): 899-904. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067-013-2227-1>. Go to original source... Go to PubMed...
    24. Brey RL, Holliday SL, Saklad AR et al. Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions. Neurology 2002; 58(8): 1214-1220. Go to original source... Go to PubMed...
    25. Sneddon IB. Cerebrovascular lesions and livedo reticularis. Br J Dermatol 1965; 77: 180-185. Go to original source... Go to PubMed...
    26. Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 2006; 15(4): 191-197. Dostupné z DOI: <http://dx.doi.org/10.1191/0961203306lu2272rr>. Go to original source... Go to PubMed...
    27. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991; 34(12): 1538-1545. Go to original source... Go to PubMed...
    28. Stojan G, Baer AN. Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol 2012; 8(5): 439-453. Dostupné z DOI: <http://dx.doi.org/10.1586/eci.12.36>. Go to original source... Go to PubMed...
    29. Horák P, Tegzová D, Závada J et al. Doporučení České revmatologické společnosti pro léčbu nemocných se SLE. Čes Revmatol 2013; 21(3): 110-122.
    30. Xiong W, Lahita RG. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol 2014; 10(2): 97-107. Dostupné z DOI: <http://dx.doi.org/10.1038/nrrheum.2013.157>. Go to original source... Go to PubMed...
    31. Dall'era M, Chakravarty EF. Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep 2011; 13(4): 308-316. Dostupné z DOI: <http://dx.doi.org/10.1007/s11926-011-0186-6>. Go to original source... Go to PubMed...
    32. Van Vollenhoven RF, Mosca M, Bertsias G et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014; 73(6): 958-967. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2013-205139>. Go to original source... Go to PubMed...
    33. Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association - European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71(11): 1771-1782. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2012-201940>. Go to original source... Go to PubMed...
    34. Ruffatti A, Salvan E, Del Ross T et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study Thromb Haemost 2014; 112(4): 727-735. Dostupné z DOI: <http://dx.doi.org/10.1160/TH14-03-0191>. Go to original source... Go to PubMed...
    35. Berman H, Rodríguez-Pintó I, Cervera R et al. Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013; 12(11): 1085-1090. Dostupné z DOI: <http://dx.doi.org/10.1016/j.autrev.2013.05.004>. Go to original source... Go to PubMed...
    36. Vymětal J, Skácelová M, Smržová A et al. Emergency situations in rheumatology with a focus on systemic autoimmune diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Republic 2016; 160(1): 20-29. Dostupné z DOI: <http://dx.doi.org/10.5507/bp.2016.002>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.